Overview
The study aims to evaluate the effects of an oral supplementation based on inositols and alpha-lactalbumin on principals metabolic parameters in patients with metabolic syndrome at risk of cardiac fibrosis
Eligibility
At least 3 of the following inclusion criteria:
- triglycerides levels ≥ 150 mg/dL
- HDL ≤ 40 mg/dL
- Fasting glycemia > 100 mg/dL <126 mg/dl
- Systolic Pressure ≥ 130 mmHg or Diastolic pressure ≥ 85 mmHg
- Hip circumference > 102 cm in men or 88 cm in women